RxDoctor Payments DataLook up a doctor →

Alaa Younes, MD

Interventional Cardiology · Alexandria, LANPI 1336112861

Payments from drug & device makers

$41,843in general payments, 2019–2025

Across 959 payments — averaging $43.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$10K
  • Pfizer$9K
  • Edwards Lifesciences$5K
  • Medtronic$3K
  • Philips North America LLC$2K
  • Novartis$1K
  • plus $11K from 39 others

What the payments were for

  • Consulting fees$9002%
  • Speaking & faculty fees$15,78238%
  • Travel & lodging$7,65518%
  • Food & beverage$17,31741%
  • Education$1880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,843 in reported general payments places this provider in the 70th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$793,916
Medicare patients
1,533
Services billed
6,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,067$775,783
EntrestoSacubitril/Valsartan423$347,590
XareltoRivaroxaban111$82,669
Repatha SureclickEvolocumab82$80,036
FarxigaDapagliflozin Propanediol92$63,823
VascepaIcosapent Ethyl93$41,223
BrilintaTicagrelor60$31,708
Praluent PenAlirocumab25$22,656
MultaqDronedarone Hcl19$17,332
Metoprolol Succinate1,050$11,222
VerquvoVericiguat12$9,395
Rosuvastatin Calcium646$8,822
Repatha SyringeEvolocumab15$8,518
JardianceEmpagliflozin12$8,258
Dofetilide23$7,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$9,192$775,7831,067 claims
NovartisEntresto$1,418$347,590423 claims
AstraZenecaFarxiga, Brilinta$796$95,531152 claims
Johnson & JohnsonXarelto$605$82,669111 claims
Sanofi-aventis U.S. LLCMultaq$518$17,33219 claims
MerckVerquvo$500$9,39512 claims
Boehringer IngelheimJardiance$425$8,25812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →